XML 72 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity (Tables)
 6 Months Ended
Jun. 30, 2017
Stockholders' Equity Note [Abstract]  
Schedule of stock-based compensation
The following table summarizes stock-based compensation expense related to all of the Company’s stock awards included in operating expense categories, as follows:
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
 
2017
 
2016
 
2017
 
2016
 
 
 
 
(Restated)
 
 
 
(Restated)
Cost of revenues
 
$
471

 
$
1,362

 
$
2,208

 
$
2,916

Research and development
 
953

 
2,032

 
2,980

 
3,811

Selling, general and administrative
 
1,214

 
4,294

 
5,561

 
8,751

Total stock-based compensation expense
 
$
2,638

 
$
7,688

 
$
10,749

 
$
15,478

The following table summarizes information about stock-based compensation:
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
 
2017
 
2016
 
2017
 
2016
 
 
 
 
(Restated)
 
 
 
(Restated)
Stock options
 
$
1,535

 
$
2,209

 
$
2,988

 
$
3,968

Restricted stock awards
 
1,036

 
5,283

 
7,431

 
11,060

Employee Stock Purchase Plan
 
67

 
196

 
330

 
450

Total stock-based compensation before taxes
 
$
2,638

 
$
7,688

 
$
10,749

 
$
15,478

Tax benefit
 
$
506

 
$
2,655

 
$
1,713

 
$
5,363
Schedule of fair value assumptions
The weighted-average assumptions used in the Black-Scholes option pricing model are as follows: 
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
 
2017
 
2016
 
2017
 
2016
 
 
 
 
(Restated)
 
 
 
(Restated)
Expected stock price volatility
 
53.2
%
 
43.6
%
 
49.2
%
 
43.4
%
Risk-free interest rate
 
1.7
%
 
1.2
%
 
1.7
%
 
1.2
%
Expected life of options (in years)
 
4.05

 
4.00

 
4.03

 
4.00

Expected dividend yield
 
—
%
 
—
%
 
—
%
 
—
%
Weighted-average fair value (grant date) of the options
 
$
6.87

 
$
12.49

 
$
7.79

 
$
11.07
Schedule of information about stock options outstanding
The following table summarizes information about stock options outstanding:
Options
 
Number of
Options
 
Weighted-
Average
Exercise Price
 
Weighted-
Average
Remaining
Contractual
Term (Years)
 
Aggregate
Intrinsic
Value
Outstanding at December 31, 2016 (Restated)
 
2,306

 
$
32.43

 
 
 
 
Options Granted
 
1,380

 
20.61

 
 
 
 
Options Exercised
 
(104
)
 
23.68

 
 
 
 
Options Cancelled
 
(440
)
 
30.74

 
 
 
 
Outstanding at June 30, 2017
 
3,142

 
$
27.76

 
3.89
 
$
597

Vested and expected to vest June 30, 2017
 
3,073

 
$
27.66

 
3.87
 
$
597

Vested and exercisable at June 30, 2017
 
1,287

 
$
31.75

 
2.96
 
$
24
Schedule of total intrinsic value for options exercised and fair value of vested options
The below table summarizes additional information related to the Company’s awards for the three and six months ended June 30, 2017: 
 
Three Months Ended June 30,
 
Six Months Ended
 June 30,
 
2017
 
2016
 
2017
 
2016
 
 
 
(Restated)
 
 
 
(Restated)
Total intrinsic value for stock options exercised
$
11

 
$
1,780

 
$
1,007

 
$
3,639
Schedule of unvested restricted stock
A summary of the Company’s non-vested restricted stock at June 30, 2017, and changes during the six months ended June 30, 2017, is presented below:
Non-Vested Restricted Stock
 
Number of
Awards
 
Weighted- Average
Grant Date
Fair Value
Non-vested at December 31, 2016 (Restated)
 
1,645

 
$
36.27

Granted
 
1,798

 
21.45

Vested
 
(702
)
 
32.34

Forfeited
 
(491
)
 
28.15

Non-vested at June 30, 2017
 
2,250

 
$
27.43